- Home
- RCUS vs ACP Comparison
RCUS vs ACP Comparison
Compare RCUS & ACP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- ACP
- Stock Information
- Founded
- RCUS 2015
- ACP 2010
- Country
- RCUS United States
- ACP United States
- Employees
- RCUS N/A
- ACP N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- ACP Investment Managers
- Sector
- RCUS Health Care
- ACP Finance
- Exchange
- RCUS Nasdaq
- ACP Nasdaq
- Market Cap
- RCUS 906.4M
- ACP 737.8M
- IPO Year
- RCUS 2018
- ACP N/A
- Fundamental
- Price
- RCUS $9.60
- ACP $5.96
- Analyst Decision
- RCUS Buy
- ACP
- Analyst Count
- RCUS 8
- ACP 0
- Target Price
- RCUS $20.86
- ACP N/A
- AVG Volume (30 Days)
- RCUS 891.1K
- ACP 337.9K
- Earning Date
- RCUS 08-07-2025
- ACP 01-01-0001
- Dividend Yield
- RCUS N/A
- ACP 17.79%
- EPS Growth
- RCUS N/A
- ACP N/A
- EPS
- RCUS N/A
- ACP N/A
- Revenue
- RCUS $141,000,000.00
- ACP N/A
- Revenue This Year
- RCUS N/A
- ACP N/A
- Revenue Next Year
- RCUS $28.73
- ACP N/A
- P/E Ratio
- RCUS N/A
- ACP N/A
- Revenue Growth
- RCUS N/A
- ACP N/A
- 52 Week Low
- RCUS $6.50
- ACP $5.55
- 52 Week High
- RCUS $18.98
- ACP $7.17
- Technical
- Relative Strength Index (RSI)
- RCUS 53.46
- ACP 58.00
- Support Level
- RCUS $9.14
- ACP $5.93
- Resistance Level
- RCUS $9.62
- ACP $5.98
- Average True Range (ATR)
- RCUS 0.44
- ACP 0.04
- MACD
- RCUS 0.04
- ACP -0.00
- Stochastic Oscillator
- RCUS 62.85
- ACP 72.22
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.